Business Context and Reporting Period
Company: Alcon, Inc. (Swiss corporation, majority-owned subsidiary of Nestlé S.A.)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Three and six months ended June 30, 2004
Filing Date: July 29, 2004
Alcon operates globally in the ophthalmic market through two segments: Alcon United States and Alcon International. The company markets pharmaceuticals, surgical equipment/devices, and consumer eye care products.
Key Financial Metrics
| Metric (in millions) | 3 Months Ended June 30, 2004 |
6 Months Ended June 30, 2004 |
|---|---|---|
| Sales | $1,039.2 | $2,002.8 |
| Gross Profit | $765.0 | $1,438.8 |
| Gross Margin | 73.6% | 71.8% |
| Operating Income | $347.7 | $624.3 |
| Net Earnings | $299.2 | $490.2 |
| Diluted EPS | $0.96 | $1.58 |
| Operating Cash Flow | N/A | $462.3 |
| Cash & Equivalents (End of Period) | $844.2 | $844.2 |
| Total Debt | $1,165.9 | $1,165.9 |
| Net Debt | $321.7 | $321.7 |
Material Changes vs. Prior Period
- Revenue Growth: Sales increased 12.3% (Q2) and 15.6% (YTD) compared to 2003. Constant currency growth was 9.9% (Q2) and 11.3% (YTD), driven by volume growth in most markets.
- Profitability: Net earnings surged 67.9% in Q2 and 58.9% YTD. This was driven by higher gross profit, lower interest expense, and a significant one-time tax benefit.
- Tax Impact: The effective tax rate dropped to 12.3% in Q2 (vs. 30.4% in 2003) due to a $57.6 million current tax benefit from amended returns and resolved audit issues. Excluding this, the annual effective rate is estimated at 30%.
- Product Performance:
- Pharmaceuticals: Strong growth in glaucoma products (Travatan, Azopt) and infection products (Vigamox). Otic products grew 24.5% (Q2) due to Ciprodex.
- Surgical: Cataract equipment sales increased over 130% (Q2) driven by the Infiniti vision system. Refractive equipment sales declined due to competition.
- Consumer: Artificial tears grew 13.8% (Q2) led by Systane.
- Debt Reduction: Total debt decreased from $1,410.3 million (Dec 31, 2003) to $1,165.9 million (June 30, 2004). Net debt remained stable at $321.7 million.
Guidance, Outlook, and Risks
- Outlook: Management expects R&D expenses to increase in the second half of 2004. Launch expenses for RETAANE are also expected to rise. The FDA approval of an expanded treatment range for CustomCornea is expected to drive future refractive sales growth.
- Capital Allocation: The company paid $169.4 million in dividends and repurchased $173.1 million of treasury shares in the first six months of 2004. A new share repurchase program of up to 4 million shares was authorized in February 2004.
- Risks:
- Currency: Significant exposure to foreign exchange rates; a 10% depreciation could decrease pre-tax earnings by ~$1.0 million (hedged).
- Competition: Patent expirations (e.g., Ciloxan) and competitive conditions in the refractive equipment market.
- Regulatory: Changes in reimbursement procedures and government legislation.
- Interest Rates: Majority of debt is short-term floating rate; a 1% rate increase would decrease pre-tax earnings by $1.1 million.
- Unusual Items: The $57.6 million tax benefit is a non-recurring item. The company also entered an agreement in June 2004 to buy out remaining license obligations for $80.6 million.
Investor Verification Checklist
- Verify the sustainability of the 12.3% effective tax rate, noting the $57.6 million one-time benefit; the normalized rate is ~30%.
- Monitor the impact of the Ciloxan patent expiration on infection product sales versus the uptake of Vigamox.
- Assess the trajectory of refractive equipment sales following the decline in Q2 and the new FDA approval for CustomCornea.
- Review the company's ability to maintain gross margins amidst currency fluctuations and potential price pressures.
- Confirm the status of the $80.6 million license buyout payment scheduled for Q3 2004.